Globe Life (GL) has just rounded out Q4 2025 with total revenue of US$1.5 billion and net income of US$266.1 million, translating to basic EPS of US$3.35 on a trailing 12 month EPS base of US$14.27 and a net margin of 19.4%. Over the past six reported quarters, revenue has moved from US$1.5 billion in Q4 2024 to US$1.5 billion in Q4 2025, while quarterly EPS ranged between about US$3.05 and US$4.81. This gives investors a steady stream of profitability markers to track into the Q1 2026 release. With net margins higher over the last 12 months and a consistent earnings record, the latest results set up a margins focused read on where the business is adding value.

See our full analysis for Globe Life.

With the headline numbers in place, the next step is to see how this earnings run rate lines up with the dominant narratives around Globe Life's growth, risks and long term profitability profile.

Margins stay solid with 19.4% net income

• Over the trailing 12 months Globe Life generated US$5.99b of revenue and US$1.16b of net income, which works out to a 19.4% net margin compared with 18.5% a year earlier.
• Bulls point to this margin profile as evidence of durable profitability, yet the earnings growth numbers give you a mixed read:
  • The bullish view highlights multi year EPS growth of about 8.5% per year and expects earnings to reach about US$1.3b by 2028, while the latest trailing figure is US$1.16b, so the gap that needs to be closed is meaningful rather than trivial.
  • At the same time, the latest trailing 12 month basic EPS of US$14.27 already sits above the consensus 2028 EPS expectation of US$17.17, so investors can clearly see that a large part of the earnings journey the bullish camp expects has already been reflected in the recent numbers.

Globe Life’s earnings resilience and margin profile are a big part of why some investors lean optimistic, so if you want to see how the bullish story is built from these figures, check out the 🐂 Globe Life Bull Case.

P/E of 10.3x and DCF fair value gap

• Globe Life trades on a P/E of 10.3x versus about 11.5x for the broader US insurance industry and 13.2x for peers, and it is also flagged as trading well below a DCF fair value of roughly US$348.62 while the current share price is US$153.97.
• Consensus narrative leans on this valuation gap as a key support, but the growth profile keeps expectations in check:
  • Analysts see revenue growing around 5.1% per year and earnings about 4.1% per year, which is slower than some broader US market forecasts, so part of the lower P/E multiple is tied to these more modest growth assumptions.
  • Even with that, the shares are described as trading roughly 55.8% below the stated DCF fair value, which means anyone relying on that model needs to be comfortable that 19.4% margins and multi year earnings growth around 8.5% can continue to support that kind of valuation gap.

High leverage meets slower expected growth

• On top of US$1.16b of trailing net income and a 55% combined ratio over the last 12 months, Globe Life is flagged as having a high level of debt, so the balance sheet is an important part of the story alongside earnings.
• Bears focus on this leverage and slower expected growth as potential pressure points, and the recent data gives them some support as well as some pushback:
  • Bears argue that higher health claim costs and regulatory scrutiny could squeeze margins, and slower forecast earnings growth of about 4.1% a year would make it harder to grow out of that debt load compared with the 8.5% annual earnings growth seen over the past five years.
  • On the other hand, the recent improvement in trailing net margin from 18.5% to 19.4% and a combined ratio moving from 59% in early 2024 to 55% on a trailing basis show that, so far, profitability metrics have stayed firm even with those balance sheet concerns in the background.

If you want to see how the more cautious camp frames these debt and growth risks against the recent numbers, it is worth reading the detailed bear case for Globe Life via the 🐻 Globe Life Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Globe Life on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, the sentiment around Globe Life is finely balanced. Move quickly to review the full picture and weigh the 4 key rewards and 2 important warning signs

See What Else Is Out There

Globe Life combines high leverage with slower expected earnings growth, so relying on margins alone could leave you more exposed to balance sheet risk than you would like.

If that trade off feels uncomfortable, shift your focus toward companies with stronger financial footing and run a quick check using the solid balance sheet and fundamentals stocks screener (42 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.